Emerging Topical Therapies: Nonsteroidal Treatments, JAK/PDE4 Inhibitors, CTCL Innovations, and Anti-Aging Approaches

Conclusions

• The presentation concludes that topical nonsteroidal therapies are increasingly preferred because they can treat inflammatory skin disease effectively while avoiding many steroid-related adverse effects.
• It suggests that advanced topical nonsteroidal agents are especially useful for atopic dermatitis, improving itch, quality of life, and longer-term disease control with good tolerability and no routine lab monitoring.
• The talk indicates that topical ruxolitinib is effective and safe for mild-to-moderate atopic dermatitis in children as young as 2 years old.
• It concludes that topical ruxolitinib also shows promising benefit in prurigo nodularis and hidradenitis suppurativa, with meaningful reductions in itch and lesion burden.
• The presentation suggests that topical JAK inhibitors may have broad off-label potential across several difficult dermatoses, although much of the evidence remains limited to case reports or early studies.
• It concludes that delgocitinib is an effective topical option for chronic hand eczema and may also have promise in frontal fibrosing alopecia and other off-label inflammatory conditions.
• It suggests that roflumilast cream is an effective steroid-free therapy for atopic dermatitis in young children and may be expanding into even younger age groups.
• The presentation concludes that hypericin photodynamic therapy may be a useful new topical approach for early-stage cutaneous T-cell lymphoma, with lesion improvement seen over time.
• It suggests that diamond core nanodiamond-zinc oxide technology may help manage photodamage and actinic injury while potentially supporting wound healing and reducing carcinogenic risk.
• The talk concludes that these emerging topical therapies collectively represent a major expansion of the dermatology toolbox and are likely to remain important in future practice.